Fair value · GENMAB A/S (GMAB) · updated 2026-10-03 · from 20-F FY2025
GENMAB A/S trades at $34.81. We are not reading assumptions out of that price: financials are filed in DKK; our prices are in USD, so these methods need a conversion we do not yet publish.
Everything below is unaffected: the filed statements, the filing they came from, and GMAB’s growth history are all as reported.
The filing behind these numbers
GENMAB A/S- Revenue
- DKK 3.7B
- Diluted EPS
- DKK 1.54
- Free cash flow
- DKK 1.1B
- operating cash flow − capital expenditure
- Diluted shares
- 62.7M
- weighted average
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-02-17 · accession 0001434265-26-000014
Open this filing on sec.govNeed GMAB data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.